CSL Ltd
AUAUDCSL Ltd (US:CMXHF) — Biotechnology. Biržu skaits, kurās tiek tirgotas uzņēmuma akcijas: 2. Šajā lapā — cena un grafiks, dividendes, lielākie akcionāri un akciju skaita vēsture.
Par uzņēmumu
- Tīmekļvietne
- csl.com.au
- Investoru attiecības
- investors.csl.com/
- Nozare
- Healthcare · Biotechnology
- Galvenā mītne
- Melbourne, Australia
- Izpilddirektors
- Mr. Gordon Naylor BEng (Hons), C.P.A., DipCompSc, M.B.A.
- Darbinieki
- 29 000
- Dibināts
- 1994
- Apgrozībā esošās akcijas
- 479.88 milj.
- Brīvā apgrozība
- 478.53 milj.
- Tirgus kapitalizācija
- 87.08 mljrd. AUD
- Iekšējās personas
- 0.02%
- Institucionālie investori
- 38.27%
Apraksts
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. The company's therapeutic areas includes Immunoglobulins, Immunology, Immunology Haematology, Cardiovascular and Renal, and Vaccines. It also licenses CSL intellectual property. It also develops vaccines for the prevention of infectious disease. The company has strategic collaboration with Dutch biotech company VarmX BV for the development of VMX-C001 to help restore blood coagulation in patients requiring urgent surgery; and Alentis Therapeutics AG to develop and commercialise lixudebart for rare kidney and liver diseases. The company was formerly known as Commonwealth Serum Laboratories Limited and later changed its name to CSL Limited in October 1991. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
Dividendes
Dividenžu izmaksas netika atrastas (pārbaudīts 09.10.2026). Uzņēmums, visticamāk, nemaksā dividendes.
Ziņas šonedēļ
Ziņu no uzņēmuma vietnes vēl nav.
Lielākie akcionāri
| Turētājs | Daļa | Akcijas | Pārskata datums |
|---|---|---|---|
| VANGUARD STAR FUNDS-Vang… | 1.49% | 7.16 milj. | 2026-07-31 |
| VANGUARD TAX-MANAGED FUN… | 0.99% | 4.75 milj. | 2026-06-30 |
| iShares Trust-iShares Co… | 0.75% | 3.6 milj. | 2026-08-31 |
| Fidelity Concord Street… | 0.39% | 1.89 milj. | 2026-07-31 |
| iShares Trust-iShares MS… | 0.36% | 1.72 milj. | 2026-08-31 |
| J.P. Morgan Exch-Trd Fd.… | 0.3% | 1.45 milj. | 2026-07-31 |
| Fidelity Salem Street TR… | 0.29% | 1.38 milj. | 2026-07-31 |
| iShares Trust-iShares MS… | 0.28% | 1.35 milj. | 2026-08-31 |
| VANGUARD Intl Eqy. INDEX… | 0.24% | 1.16 milj. | 2026-07-31 |
| SCHWAB STRATEGIC TRUST-S… | 0.22% | 1.08 milj. | 2026-05-31 |
| Pacer Advisors, Inc. | 0.08% | 369 774 | 2026-06-30 |
| Naylor (Gordon) (Directo… | ≈0.01% | 40 819 | 2026-05-26 |
| McKenzie (Paul F) (Chief… | ≈0.01% | 31 053 | 2025-09-01 |
| McNamee (Brian Anthony)… | ≈0.01% | 30 561 | 2026-08-21 |
| Linton (Joy) (Chief Fina… | ≈0% | 15 096 | 2025-06-30 |
| Watkins (Alison Mary) (I… | ≈0% | 6 989 | 2026-08-21 |
| Clark (Megan Elizabeth)… | ≈0% | 5 718 | 2025-08-22 |
| Schmeltz (Andy) (Other E… | ≈0% | 5 067 | 2025-06-30 |
| Hewson (Carolyn Judith)… | ≈0% | 4 131 | 2026-08-21 |
| Price (Cameron Bruce) (I… | ≈0% | 3 559 | 2026-08-21 |
| Daniels (Brian M.D.) (No… | ≈0% | 3 400 | 2025-11-18 |